Sub-antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium ATPase expression and function following cardiac hypertrophy in rats

Journal of Molecular and Cellular Cardiology

Volumn 30, Issue 12, 1998, Pages 2683-2694

  Boateng, Samuel Y ^a   Seymour, Anne Marie L ^c   Bhutta, Nabeela S ^a   Dunn, Michael J ^a   Yacoub, Magdi H ^a   Boheler, Kenneth R ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Cardiac hypertrophy; Phospholamban; Protein; Regression; RNA; SR CaATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALSEQUESTRIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; PHOSPHOLAMBAN; RAMIPRIL;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA SYNTHESIS; SARCOPLASMIC RETICULUM;

ANIMALIA;

EID: 0032445050     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1998.0830     Document Type: Article

References (48)

1. 2+ pumps in heart and diaphragm of cardiomyopathic hamster: effects of perindopril. Am J Physiol 268: H1947-H1953.
2. ARAI M, MATSUI H, PERIASAMY M, 1994. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 74: 555-564.
3. BAKER K, BOOZ G, DOSTAL D, 1992. Cardiac action of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54: 227-241.
4. BLOSE LH, 1988. Cellular protein databases: a new approach to the study of genomic organisation and function of the cell. Leukaemia 2: 559.
5. BOATENG SY, SEYMOUR AM, DUNN MJ, YACOUB MH, BOHELER KR, 1997. Inhibition of endogenous cardiac phosphatase activity and meaurement of sarcoplasmic reticulum calcium uptake: A possible role of phospholamban phosphorylation in the hypertrophied myocardium. Biochem Biophys Res Comm 239: 701-705.
6. BRADFORD MM, 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72: 248-254.
7. BRISTOL MR, ABRAHAM WT, 1995. Anti-adrenergic effects of angiotensin converting enzyme inhibitors. Eur Heart J 16: 37-41.
8. BRUCKSCHLEGEL G, HOLMER SR, JANDELEIT K, GRIMM D, MUDERS F, KROMER EP, REIGGER GAJ, SCHUNKERT H, 1995. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension 25: 250-259.
9. CATRAVAS JD, WATKINS CA, 1985. Plasmalemmal metabolic activities in cultured calf pulmonary arterial endothelial cells. Res Commun Chem Pathol Pharmacol 50: 163-179.
10. CHOMCZYNSKI P, SACCHI N, 1987. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 162: 156-159.
11. COUMANS JVF, YEOH T, SEETO RK, KEOGH A, BRENNAN K, GUNNING P, HARDEMAN E, DOS REMEDIOS CG, 1997. Variations in the relative mRNA levels of actins and myosin heavy chains do not produce corresponding differences in their proteins in the adult human heart. J Mol Cell Cardiol 29: 895-905.
12. 2+-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 66: 554-564.
13. DUNN MJ, 1987. Two-dimensional polyacrylamide gels for the construction of protein databases. In: Bryce CFA (ed) Microcomputers in Biochemistry. IRL Press, Oxford, pp. 215.
14. DZAU VJ, 1992. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol 70: 4C-11C.
15. FELDMAN AM, WEINBERG EO, RAY PE, LORELL BH, 1993. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 73: 184-192.
16. GOHLKE P, LINZ W, SCHOLKENS BA, KUWER I, BARTENBACH S, SCHNELL A, UNGER T, 1994. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 23: 411-418.
17. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 75: 434-442.
18. HIRSCH AT, TALSNESS CE, SCHUNKERT H, PAUL M, DZAU VJ, 1991. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 69: 475-482.
19. HIRSCH AT, TALSNESS CE, SMITH AD, SCHUNKERT H, INGELFINGER JR, DZAU VJ, 1992. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 86: 1566-1574.
20. HOLTZ J, STUDER R, REINECKE H, JUST H, DREXLER H, 1992. Modulation of myocardial sarcoplasmic reticulum Ca(++)-ATPase in cardiac hypertrophy by angiotensin converting enzyme? Basic Res Cardiol 87 Suppl 2: 191-204.
21. IKEMOTO F, SONG GB, TOMINAGA M, YAMAMOTO K, 1989. Endogenous inhibitor of angiotensin converting enzyme in the rat heart. Biochem Biophys Res Commun 159: 1093-1099.
22. KOBAN MU, BOATENG SY, BOHELER KR, 1997. The role of the sarcoplasmic reticulum Calcium ATPase and its regulatory protein phospholamban in the developing myocardium. In: Ostadal B, Nagano M, Takeda N, Dhalla NS (eds) The Developing Heart. Lippincott-Ravens Publishers, New York, pp. 143-164.
23. Koss KL, PONNIAH S, JONES WK, GRUPP IL, KRANIAS EG, 1995. Differential phospholamban gene expression in murine cardiac compartments. Molecular and physiological analyses. Circ Res 77: 342-353.
24. LATIF N, BAKER CS, DUNN MJ, ROSE ML, BRADY P, YACOUB MH, 1993. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol 22: 1378-1384.
25. LIMAS CJ, OLIVARI MT, GOLDENBERG IF, LEVINE TB, BENDITT DG, SIMON A, 1987. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 21: 601-605.
26. LINZ W, SCHAPER J, WIEMER G, ALBUS G, SCHOLKENS BA, 1992. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: on one year study in rats. Br J Pharmacol 107: 970-975.
27. LINZ W, SCHOLKENS BA, 1992a. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 20 Suppl 9: S83-90.
28. LINZ W, SCHOLKENS BA, 1992b. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 105: 771-772.
29. 2+-ATPase mRNA. FEBS Lett 249: 35-41.
30. LOMPRÉ A, ANGER M, LEVITSKY D, 1994. Sarco-(endo)plasmic reticulum calcium pumps in the cardiovascular system: function and gene expression (Review). J Mol Cell Cardiol 26: 1109-1121.
31. LUO W, GRUPP IL, HARRER J, PONNIAH S, GRUPP G, DUFFY JJ, DOETSCHMAN T, KRANIAS EG, 1994. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 75: 401-409.
32. MICHEL JB, MERCADIER JJ, GALEN FX, URBAIN R, DUSSAULE JC, PHILIPPE M, CORVOL P, 1990. Urinary cyclic guanosine monophosphate as an indicator of experimental congestive heart failure in rats. Cardiovasc Res 24: 946-952.
33. MIYATA S, HANEDA T, 1994. Hypertrophic growth of cultured neonatal rat heart cells mediated by type I angiotensin II receptor. Am J Physiol 266: H2443-H2451.
34. MIZUNO K, TANI M, HASHIMOTO S, NIIMURA S, SANADA H, WATANABE H, OHTSUKI M, FUKUCHI S, 1992. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardic hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sciences 51: 367-374.
35. MOORMAN AF, VERMEULEN JL, KOBAN MU, SCHWARTZ K, LAMERS WH, BOHELER KR, 1995. Patterns of expression of sarcoplasmic reticulum Ca(2+)-ATPase and phospholamban mRNAs during rat heart development. Circ Res 76: 616-625.
36. MORGAN JP, ERNY RE, ALLEN PD, GROSSMAN W, GWATHMEY JK, 1990. Abnormal intracellular calcium handling: a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 81 Suppl III: 21-32.
37. MOVSESIAN MA, SCHWINGER RH, 1998. Calcium sequestration by the sarcoplasmic reticulum in heart failure. Cardiovasc Res 37: 352-359.
38. NAQVI RU, MACLEOD KT, 1994. Effect of hypertrophy on mechanisms of relaxation in isolated cardiac myocytes from guinea pig. Am J Physiol 267 (36): H1851-H1861.
39. PETROU M, WYNNE DG, BOHELER KR, YACOUB MH, 1995. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation 92: 483-489.
40. 2+-ATPase gene is regulated at the transcriptional level during compensated left ventricular hypertrophy in the rat. C.R. Acad. Sci. Paris 320: 963-969.
41. ROCKMAN HA, WACHORST SP, MAO L, ROSS, JR. 1994. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 266: H2468-H2475.
42. SCHROR K, 1992. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 20 Suppl 9: S68-73.
43. SCHUNKERT H, DZAU VJ, TANG SS, HIRSCH AT, APSTEIN CS, LORELL BH, 1990. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest 86: 1913-1920.
44. SCHUNKERT H, INGELFINGER JR, HIRSCH AT, PINTO Y, REMME WJ, JACOB H, DZAU VJ, 1993. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 73: 312-318.
45. 2+ exchanger in endstage human heart failure. Circ Res 75: 443-453.
46. THANDROYEN FT, MORRIS AC, HAGLER HK, ZIMAN B, PAI L, WILERSON JT, BUJA LM, 1991. Intracellular calcium transients and arrhythmias in isolated heart cells. Circ Res 69: 810-819.
47. WEINBERG EO, SCHOEN FJ, GEORGE D, KAGAYA Y, DOUGLAS PS, LITWIN SE, SCHUNKERT H, BENEDICT CR, LORELL BH, 1994. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90: 1410-1422.
48. 2+-ATPase gene expression in renal hypertensive rats:dose-dependent effects of ACE inhibition and AT1-receptor blockade. Cardiovasc Res 31: 758-768.